Previous data suggest that PD1/PDL1 inhibitor-associated myopathy may present with a wide range of clinical manifestations and degrees of severity including MG [81,87,88], necrotising myopathy [89,90,91] or even lethal cardiomyopathy [92,93,94,95]. Here, CD274 is linked to myopathy.